Join us at #ASCO24 as we present data highlighting important developments in cancer care using liquid biopsy to identify epigenomic biomarkers. Visit booth 28115 to learn more.
Guardant Health’s Post
More Relevant Posts
-
Introducing a new "OvaView" summary featuring Victoria Haverbusch, our expert in risk assessment. Explore the latest advancements in biomarker technology for assessing ovarian cancer risk in a concise video and gain valuable insights to enrich your clinical decision-making process. #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth
To view or add a comment, sign in
-
The surge in cancer instances highlights the crucial role radiotheranostics plays in transforming global healthcare. Per The Business Research Company’s Radiotheranostics Global Market Report 2023, Cancer Research UK reported 18 million new cancer cases, with projections foreseeing a staggering 54.9% increase by 2040, reaching 28 million cases annually. Understand how radiotheranostics medicines stand at the forefront, offering the promise of personalized treatment through diagnostic and therapeutic radionuclide probes. Explore our comprehensive report for an in-depth analysis radiotheranostics market: https://lnkd.in/dJP5P3Vu . . . #radiotheranostics #radiopharmaceuticals #targetedradiotreatmen #cancerresearch #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence
To view or add a comment, sign in
-
📢 New article in Oncology Issues (July 2023) ACCC shares a look at the current NTRK testing landscape and identifies effective ways to optimize comprehensive biomarker testing in practice. Gathered by a series of focus groups with multidisciplinary care team members from cancer programs nationwide, this article also explores barriers to testing and common misconceptions related to NTRK testing. 🔗 Read the entire article, “Emerging Biomarkers: Innovative Therapies for Rare Disease,” by Joseph Kim, MD, MPH, MBA, FACHEF. https://lnkd.in/eMJThrGy #Biomarkers #CancerCare #RareDisease
To view or add a comment, sign in
-
-
Clinical Business Manager, ANZ | Champion for Change | Precision Health | Leadership | Stakeholder Engagement | Strategy & Business Development
Missed the below webinar? Watch on-demand. 💻⏰ Did you know that turnaround times (TATs) for #oncology #biomarker profiling can be as long as 25 days? This extended timeframe has a significant impact on patients' outcomes. Rapid molecular profiling for timely biomarker analysis can play an important role in optimizing patient outcomes. 🧬💊🩺 #precisiononcology #personalisedmedicine #precisionhealth #genomicsinhealthcare #molecularprofiling #targetedtherapy #rapidgenomicprofiling #clinicallyactionable #NGS #rapidNGS #automatedNGS #oncomine #thermofisheremp
Live Webinar: Rapid Molecular Profiling is Essential to Optimize Patient Outcomes - Real-World Data Analysis
thepathologist.videomarketingplatform.co
To view or add a comment, sign in
-
During the 2024 #AACR Annual Meeting this week, the concept of #metastasis has dramatically changed since its last plenary session 14 years ago.... David Lyden's session on "Evolution of the Genome, Microenvironment, and Host through Metastasis" reveals new insights on the importance of tumor-secreted factors and extracellular vesicles (EVPs) which can have downstream effect on different organs and can contribute towards a systemic effect. As Lyden's team discovered, EVPs as a result of a pancreatic tumor can disrupt the liver's function, increase the side effects of chemotherapy and even increase the likelihood of metastases outside the liver. Said differently, “if you have cancer going to the lung, you can’t ignore that you have a fatty liver as well.” The evolving understanding of metastasis emphasizes the need for a more comprehensive approach to cancer research and treatment. To learn more about his work and conference insights, continue reading here: https://lnkd.in/g_XJB3ed #Pharmaceutical #Biotech #Diagnoses #Medicine #Clinical #Healthcare #Lifescience #CancerResearch #CancerTreatment #CancerCells #Oncology #MedicalResearch #Healthcare #CancerAwareness #CancerBiology #InnovationInMedicine #HealthcareIndustry #CancerPrevention #CancerScience #HealthScience #MedicalCommunity #CancerEducation
AACR 2024: New concepts suggest new targets for metastatic disease
bioworld.com
To view or add a comment, sign in
-
Cancer is a fibrotic disease—and last year the FDA issued a Letter of Support for the inclusion of our nordicPRO-C3™ biomarker in tumor fibrosis studies. Active tumor fibrosis is the leading factor in cold, dense, hypoxic, and collagen-rich tumors. Watch Nicholas Willumsen, Director of Oncology at Nordic Bioscience, discuss how the FDA's endorsement may impact clinical decision-making and patient outcomes. PRO-C3 is measured on the Roche Diagnostics cobas® e automated platform, increasing robustness and accuracy in sample measurements and enabling future in-vitro diagnostic (IVD) use. Morten Asser Karsdal Neel Ingemann Nissen Claus S. von Arenstorff Daniel Gabor #FDA #DrugDevelopment #TumorFibrosis #CancerReserach #ClinicalTrials
Nordic Bioscience's PRO-C3 receives FDA endorsement
To view or add a comment, sign in
-
🌐📊 Cancer Diagnostics Market Surges to USD 188.43 Billion by 2031! 📈💡 Exciting news from Cogentix Research! The cancer diagnostics market is projected to skyrocket to a staggering USD 188.43 billion by 2031, fueled by a robust 6.77% CAGR. This significant growth underscores the vital advancements and innovations in cancer diagnostics, paving the way for improved patient outcomes and enhanced healthcare solutions. Stay tuned for more insights and in-depth analysis from our expert team! #CancerDiagnostics #MarketGrowth #CogentixResearch #HealthcareInnovation #MedicalAdvancements #ResearchInsights
To view or add a comment, sign in
-
-
🌐📊 Cancer Diagnostics Market Surges to USD 188.43 Billion by 2031! 📈💡 Exciting news from Cogentix Research! The cancer diagnostics market is projected to skyrocket to a staggering USD 188.43 billion by 2031, fueled by a robust 6.77% CAGR. This significant growth underscores the vital advancements and innovations in cancer diagnostics, paving the way for improved patient outcomes and enhanced healthcare solutions. Stay tuned for more insights and in-depth analysis from our expert team! #CancerDiagnostics #MarketGrowth #CogentixResearch #HealthcareInnovation #MedicalAdvancements #ResearchInsights
To view or add a comment, sign in
-
-
MedTalks - An interview with Brian Frenzel, CEO of TOSK discussing the company's business and its investment opportunities Tosk has developed and patented two important side-effect-blocking agents, TK-90 for mucositis and pulmonary fibrosis, and TK-39 for cardiotoxicity. Sponsored by NIH SBIR grants, Tosk has also identified oncogenic KRAS-inhibiting drug candidates. These are being developed to treat KRAS-positive malignancies, including 90% of pancreatic, 45% of colon, and 35% of lung cancers. https://wix.to/kTy2wOB #tosk #familyofficeconnector #opportunityspotlight #medicalandpharmainsider #fcglobalstrategies
MedTalks - An interview with Brian Frenzel, CEO of TOSK discussing the company’s business and its investment opportunities
fcglobalstrategies.com
To view or add a comment, sign in
-
A HUGE THANK YOU to all oncologists, researchers and biopharma companies who have worked closely with us this year. Thank you for your support and confidence in Guardant Health’s comprehensive genomic profiling tests which are transforming cancer care across all stages of the disease. As we move into 2024, we look forward to your continued support in guiding treatment decisions for patients with cancer in Asia, Middle East and Africa. Patient centricity is the heart of all that we do. We serve each patient like a family member. Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. #guardanthealth #guardanthealthamea #thankyou #oncologists #medicaloncologists #researchers #biopharma #cancerpatients #puttingpatientsfirst #guardant360 #guardant360tissuenext #guardantreveal #guardantresponse #shield #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #liquidissolid
To view or add a comment, sign in
-